| Volume: | 4,089,937 |
|---|---|
| Day's Low: | $52.50 |
| 52-wk Low: | $39.75 |
| Previous Close: | $53.04 |
| Dividend: | $0.13 |
| Market Cap: | 48,080,600 |
| Avg Volume: | 4,490,400 |
|---|---|
| Day's High: | $53.08 |
| 52-wk High: | $54.95 |
| Open Price: | $52.74 |
| Yield: | 0.95% |
| P/E (Forward): | 15.69 |
| 8:34 AM | 11/20/2009 | EU Panel: Affirm Benefits Of Celvapan, Focetria, Pandemrix |
| 7:03 AM | 11/12/2009 | Second Round Bids For Ratiopharm Due Mid-December - Source |
| 3:48 PM | 11/9/2009 | Merck Asks US To Reconsider Singulair Patent Rejection |
| 12:38 PM | 11/5/2009 | Merckle To Narrow Bid List For Ratiopharm In Next Few Weeks |
| 6:17 PM | 11/3/2009 | 3rd UPDATE: DOJ: Omnicare, Teva Unit To Pay In Kickbacks Case |
| 4:03 PM | 11/3/2009 | 2nd UPDATE: DOJ:Omnicare, Teva Unit To Pay In Kickbacks Case |
| 2:04 PM | 11/3/2009 | UPDATE: US DOJ: Omnicare To Pay $98 Million, Teva Unit $14 Million In Kickbacks Case |
| 11/20/2009 | Dividend Payers Return to the Fore |
| 11/19/2009 | A move into Japan isn't a bad idea, but it isn't going to save the company either. |
| 11/19/2009 | In Search of Dividends...and More |
| 11/17/2009 | Why is the fund giant losing money to competitors? |
| 11/17/2009 | In Search of Dividends...and More |
| 11/17/2009 | It's time to take off the training wheels. |
| 11/16/2009 | A Bargain Buy in the Holy Land |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.89 | 0.72 | 23.61 |
| EPS, GAAP | 0.72 | 0.77 | -6.49 |
| Consensus Estimate | 0.88 | 0.69 | 27.54 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 3.19 | 2.86 | 11.54 |
| EPS, GAAP | 0.99 | 2.29 | -56.77 |
| Consensus Estimate | 3.08 | NA | NA |
| TEVA | Industry Average | |
| P/E (TTM) | 53.25 | 81.60 |
| P/E (Forward) | 15.69 | 12.70 |
| PEG Ratio | 0.77 | 0.55 |
| Price/Sales | 3.73 | 3.90 |
| Beta | 0.20 | 0.15 |